{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:43:33Z","timestamp":1740185013758,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die 5.\u00a0Edition der WHO-Klassifikation maligner Lymphome (WHO-HAEM5) und die Internationale Konsensus-Klassifikation (ICC) zeigen, was die Einteilung aggressiver B\u2011Zell-Lymphome angeht, erfreulicherweise nur wenige Unterschiede, die unseren diagnostischen Alltag wenig beeinflussen d\u00fcrften. Auch die Neuerungen gegen\u00fcber der revidierten WHO-Klassifikation aus dem Jahr\u00a02017 (WHO-HAEM4R) sind moderat. Sie betreffen meist geringf\u00fcgige Namens\u00e4nderungen einzelner Entit\u00e4ten, Anpassung diagnostischer Kriterien oder eine Aufwertung \u201eprovisorischer\u201c zu \u201edistinkten\u201c Entit\u00e4ten. Die Definition des h\u00e4ufigsten aggressiven B\u2011Zell-Lymphoms, des diffus gro\u00dfzellige B\u2011Zell-Lymphom, nicht anderweitig klassifiziert (DLBCL, NOS), bleibt unver\u00e4ndert, eine Unterteilung in den Keimzentrumstyp bzw. Nicht-Keimzentrumstyp sehen beide Klassifikationen als wichtig an. Das DLBCL, NOS, muss im Rahmen der Routinediagnostik von anderen gro\u00dfzelligen B\u2011Zell-Lymphomen abgegrenzt werden. Dazu z\u00e4hlen das gro\u00dfzellige B\u2011Zell-Lymphom mit <jats:italic>IRF4<\/jats:italic>-Rearrangement, das in der ICC und WHO-HAEM5 zu einer definitiven Entit\u00e4t hochgestuft wurde, und das gro\u00dfzellige bzw. high-grade B\u2011Zell-Lymphom mit 11q-Aberration. Aggressive B\u2011Zell-Lymphome mit <jats:italic>MYC-<\/jats:italic> und <jats:italic>BCL2<\/jats:italic>-Rearrangement stellen biologisch eine homogene Gruppe dar und werden in beiden Klassifikationen als definitive Entit\u00e4ten gelistet. Dies gilt nicht f\u00fcr die sehr heterogene Gruppe aggressiver Lymphome mit <jats:italic>MYC<\/jats:italic>- und <jats:italic>BCL6<\/jats:italic>-Rearrangements, welche von der ICC als provisorische Entit\u00e4t anerkannt werden, w\u00e4hrend die WHO-HAEM5 diese entweder unter den DLBCL, NOS oder den hochmalignen B\u2011Zell-Lymphomen, nicht anderweitig spezifiziert (HGBL, NOS), listet.<\/jats:p>","DOI":"10.1007\/s00292-023-01187-4","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T23:18:54Z","timestamp":1679872734000},"page":"166-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Klassifikation aggressiver B-Zell-Lymphome","Classification of aggressive B-cell lymphomas"],"prefix":"10.1007","volume":"44","author":[{"given":"Andreas","family":"Rosenwald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Menter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Dirnhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"issue":"7","key":"1187_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio\u00a0R, Amador\u00a0C, Anagnostopoulos\u00a0I, Attygalle\u00a0AD, Araujo\u00a0IBO, Berti\u00a0E et\u00a0al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","journal-title":"Leukemia"},{"issue":"2","key":"1187_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/PAS.0b013e318267fabc","volume":"37","author":"S Alexanian","year":"2013","unstructured":"Alexanian\u00a0S, Said\u00a0J, Lones\u00a0M, Pullarkat\u00a0ST (2013) KSHV\/HHV8-negative effusion-based lymphoma, a\u00a0distinct entity associated with fluid overload states. Am J Surg Pathol 37(2):241\u2013249. https:\/\/doi.org\/10.1097\/PAS.0b013e318267fabc","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"1187_CR3","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo\u00a0E, Jaffe\u00a0ES, Cook\u00a0JR, Quintanilla-Martinez\u00a0L, Swerdlow\u00a0SH, Anderson\u00a0KC et al (2022) The international consensus classification of mature lymphoid neoplasms: a\u00a0report from the Clinical Advisory Committee. Blood 140(11):1229\u20131253. https:\/\/doi.org\/10.1182\/blood.2022015851","journal-title":"Blood"},{"issue":"5","key":"1187_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy\u00a0B, Stewart\u00a0C, Dunford\u00a0AJ, Kim\u00a0J, Kamburov\u00a0A, Redd\u00a0RA et\u00a0al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24(5):679\u2013690. https:\/\/doi.org\/10.1038\/s41591-018-0016-8","journal-title":"Nat Med"},{"issue":"5","key":"1187_CR5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/s41375-019-0691-6","volume":"34","author":"F Cucco","year":"2020","unstructured":"Cucco\u00a0F, Barrans\u00a0S, Sha\u00a0C, Clipson\u00a0A, Crouch\u00a0S, Dobson\u00a0R et al (2020) Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC\/BCL2 double-hit. Leukemia 34(5):1329\u20131341. https:\/\/doi.org\/10.1038\/s41375-019-0691-6","journal-title":"Leukemia"},{"issue":"5","key":"1187_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","volume":"20","author":"A Davies","year":"2019","unstructured":"Davies\u00a0A, Cummin\u00a0TE, Barrans\u00a0S, Maishman\u00a0T, Mamot\u00a0C, Novak\u00a0U et al (2019) Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B\u2011cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol 20(5):649\u2013662. https:\/\/doi.org\/10.1016\/S1470-2045(18)30935-5","journal-title":"Lancet Oncol"},{"issue":"3","key":"1187_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1200\/JCO.18.01583","volume":"37","author":"D Ennishi","year":"2019","unstructured":"Ennishi\u00a0D, Jiang\u00a0A, Boyle\u00a0M, Collinge\u00a0B, Grande\u00a0BM, Ben-Neriah\u00a0S et al (2019) Double-hit gene expression signature defines a\u00a0distinct subgroup of germinal center B\u2011cell-like diffuse large B\u2011cell lymphoma. J\u00a0Clin Oncol 37(3):190\u2013201. https:\/\/doi.org\/10.1200\/JCO.18.01583","journal-title":"J Clin Oncol"},{"issue":"7","key":"1187_CR8","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/bloodadvances.2021006034","volume":"6","author":"L Frauenfeld","year":"2022","unstructured":"Frauenfeld\u00a0L, Castrejon-de-Anta\u00a0N, Ramis-Zaldivar\u00a0JE, Streich\u00a0S, Salmeron-Villalobos\u00a0J, Otto\u00a0F et al (2022) Diffuse large B\u2011cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. Blood Adv 6(7):2361\u20132372. https:\/\/doi.org\/10.1182\/bloodadvances.2021006034","journal-title":"Blood Adv"},{"issue":"9","key":"1187_CR9","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3324\/haematol.2018.207928","volume":"104","author":"B Gonzalez-Farre","year":"2019","unstructured":"Gonzalez-Farre\u00a0B, Ramis-Zaldivar\u00a0JE, Salmeron-Villalobos\u00a0J, Balague\u00a0O, Celis\u00a0V, Verdu-Amoros\u00a0J et al (2019) Burkitt-like lymphoma with 11q aberration: a\u00a0germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. Haematologica 104(9):1822\u20131829. https:\/\/doi.org\/10.3324\/haematol.2018.207928","journal-title":"Haematologica"},{"issue":"1","key":"1187_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans\u00a0CP, Weisenburger\u00a0DD, Greiner\u00a0TC, Gascoyne\u00a0RD, Delabie\u00a0J, Ott\u00a0G et al (2004) Confirmation of the molecular classification of diffuse large B\u2011cell lymphoma by immunohistochemistry using a\u00a0tissue microarray. Blood 103(1):275\u2013282. https:\/\/doi.org\/10.1182\/blood-2003-05-1545","journal-title":"Blood"},{"key":"1187_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.humpath.2018.06.006","volume":"80","author":"SM Johnson","year":"2018","unstructured":"Johnson\u00a0SM, Umakanthan\u00a0JM, Yuan\u00a0J, Fedoriw\u00a0Y, Bociek\u00a0RG, Kaiser-Rogers\u00a0K et al (2018) Lymphomas with pseudo-double-hit BCL6-MYC translocations due to t(3;8)(q27;q24) are associated with a\u00a0germinal center immunophenotype, extranodal involvement, and frequent BCL2 translocations. Hum Pathol 80:192\u2013200. https:\/\/doi.org\/10.1016\/j.humpath.2018.06.006","journal-title":"Hum Pathol"},{"issue":"5","key":"1187_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00428-019-02698-3","volume":"476","author":"RL King","year":"2020","unstructured":"King\u00a0RL, Goodlad\u00a0JR, Calaminici\u00a0M, Dotlic\u00a0S, Montes-Moreno\u00a0S, Oschlies\u00a0I et al (2020) Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Arch 476(5):647\u2013665. https:\/\/doi.org\/10.1007\/s00428-019-02698-3","journal-title":"Virchows Arch"},{"issue":"8","key":"1187_CR13","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.3324\/haematol.2021.279631","volume":"107","author":"A Kunstner","year":"2022","unstructured":"Kunstner\u00a0A, Witte\u00a0HM, Riedl\u00a0J, Bernard\u00a0V, Stolting\u00a0S, Merz\u00a0H et al (2022) Mutational landscape of high-grade B\u2011cell lymphoma with MYC-, BCL2 and\/or BCL6 rearrangements characterized by whole-exome sequencing. Haematologica 107(8):1850\u20131863. https:\/\/doi.org\/10.3324\/haematol.2021.279631","journal-title":"Haematologica"},{"issue":"20","key":"1187_CR14","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy\u00a0SE, Barrans\u00a0SL, Beer\u00a0PA, Painter\u00a0D, Smith\u00a0AG, Roman\u00a0E et\u00a0al (2020) Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a\u00a0Haematological Malignancy Research Network report. Blood 135(20):1759\u20131771. https:\/\/doi.org\/10.1182\/blood.2019003535","journal-title":"Blood"},{"issue":"7","key":"1187_CR15","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/his.12884","volume":"68","author":"S Li","year":"2016","unstructured":"Li\u00a0S, Desai\u00a0P, Lin\u00a0P, Yin\u00a0CC, Tang\u00a0G, Wang\u00a0XJ et al (2016) MYC\/BCL6 double-hit lymphoma (DHL): a\u00a0tumour associated with an aggressive clinical course and poor prognosis. Histopathology 68(7):1090\u20131098. https:\/\/doi.org\/10.1111\/his.12884","journal-title":"Histopathology"},{"issue":"12","key":"1187_CR16","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski\u00a0GS, Chiappella\u00a0A, Gascoyne\u00a0RD, Scott\u00a0DW, Zhang\u00a0Q, Jurczak\u00a0W et al (2021) ROBUST: a phase III study of Lenalidomide plus R\u2011CHOP versus placebo plus R\u2011CHOP in previously untreated patients with ABC-type diffuse large B\u2011cell lymphoma. J\u00a0Clin Oncol 39(12):1317\u20131328. https:\/\/doi.org\/10.1200\/JCO.20.01366","journal-title":"J Clin Oncol"},{"issue":"3","key":"1187_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","volume":"37","author":"RK Pillai","year":"2013","unstructured":"Pillai\u00a0RK, Sathanoori\u00a0M, Van Oss\u00a0SB, Swerdlow\u00a0SH (2013) Double-hit B\u2011cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B\u2011cell lymphomas. Am J Surg Pathol 37(3):323\u2013332. https:\/\/doi.org\/10.1097\/PAS.0b013e31826cebad","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"1187_CR18","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.3324\/haematol.2020.271957","volume":"106","author":"JE Ramis-Zaldivar","year":"2021","unstructured":"Ramis-Zaldivar\u00a0JE, Gonzalez-Farre\u00a0B, Nicolae\u00a0A, Pack\u00a0S, Clot\u00a0G, Nadeu\u00a0F et al (2021) MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica 106(10):2682\u20132693. https:\/\/doi.org\/10.3324\/haematol.2020.271957","journal-title":"Haematologica"},{"issue":"1","key":"1187_CR19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bjh.17132","volume":"192","author":"HFP Runge","year":"2021","unstructured":"Runge\u00a0HFP, Lacy\u00a0S, Barrans\u00a0S, Beer\u00a0PA, Painter\u00a0D, Smith\u00a0A et al (2021) Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL). Br J Haematol 192(1):216\u2013220. https:\/\/doi.org\/10.1111\/bjh.17132","journal-title":"Br J Haematol"},{"issue":"15","key":"1187_CR20","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz\u00a0R, Wright\u00a0GW, Huang\u00a0DW, Johnson\u00a0CA, Phelan\u00a0JD, Wang\u00a0JQ et al (2018) Genetics and pathogenesis of diffuse large B\u2011cell lymphoma. N\u00a0Engl J Med 378(15):1396\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa1801445","journal-title":"N Engl J Med"},{"issue":"9","key":"1187_CR21","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1182\/blood-2018-07-864025","volume":"133","author":"R Wagener","year":"2019","unstructured":"Wagener\u00a0R, Seufert\u00a0J, Raimondi\u00a0F, Bens\u00a0S, Kleinheinz\u00a0K, Nagel\u00a0I et al (2019) The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma. Blood 133(9):962\u2013966. https:\/\/doi.org\/10.1182\/blood-2018-07-864025","journal-title":"Blood"},{"issue":"12","key":"1187_CR22","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","volume":"39","author":"WH Wilson","year":"2021","unstructured":"Wilson\u00a0WH, Wright\u00a0GW, Huang\u00a0DW, Hodkinson\u00a0B, Balasubramanian\u00a0S, Fan\u00a0Y et al (2021) Effect of ibrutinib with R\u2011CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell 39(12):1643\u20131653. https:\/\/doi.org\/10.1016\/j.ccell.2021.10.006","journal-title":"Cancer Cell"},{"issue":"4","key":"1187_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright\u00a0GW, Huang\u00a0DW, Phelan\u00a0JD, Coulibaly\u00a0ZA, Roulland\u00a0S, Young\u00a0RM et\u00a0al (2020) A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37(4):551\u2013568.e14. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.015","journal-title":"Cancer Cell"},{"issue":"15","key":"1187_CR24","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes\u00a0A, Sehn\u00a0LH, Johnson\u00a0P, Zinzani\u00a0PL, Hong\u00a0X, Zhu\u00a0J et al (2019) Randomized phase III trial of Ibrutinib and Rituximab plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in non-germinal center B\u2011cell diffuse large B\u2011cell lymphoma. J\u00a0Clin Oncol 37(15):1285\u20131295. https:\/\/doi.org\/10.1200\/JCO.18.02403","journal-title":"J Clin Oncol"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-023-01187-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-023-01187-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-023-01187-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T17:04:31Z","timestamp":1683219871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-023-01187-4"}},"subtitle":["Neuigkeiten und offene Fragen","News and open questions"],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1187"],"URL":"https:\/\/doi.org\/10.1007\/s00292-023-01187-4","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"type":"print","value":"2731-7188"},{"type":"electronic","value":"2731-7196"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"assertion":[{"value":"14 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Rosenwald, T.\u00a0Menter und S.\u00a0Dirnhofer geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}